Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Ital...

por Cascinu, S., Labianca, R., Graziano, F., Pancera, G., Barni, S., Frontini, L., Luporini, G., Cellerino, R., Catalano, G.
Publicado em 1998

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

por Beretta, G D, Michetti, G, Belometti, M O, Gritti, G, Quadri, A, Poletti, P, Labianca, R
Publicado em 2000

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

por Cascinu, S, Frontini, L, Comella, G, Barni, S, Labianca, R, Battelli, N, Casaretti, R, Zonato, S, Pirovano, M, Catalano, G, Cellerino, R
Publicado em 1999

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive trac...

por Cascinu, S, Graziano, F, Barni, S, Labianca, R, Comella, G, Casaretti, R, Frontini, L, Catalano, V, Baldelli, A M, Catalano, G
Publicado em 2001

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer

por Graziano, F, Santini, D, Testa, E, Catalano, V, Beretta, G D, Mosconi, S, Tonini, G, Lai, V, Labianca, R, Cascinu, S
Publicado em 2003

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies

por Mandalà, M, Grosso, F, Vitalini, C, Corradino, I, Sanfilippo, R, Colombini, S, Clerici, M, Labianca, R, De Pascale, A, Marsoni, S
Publicado em 2012

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

por Guglielmi, A, Barni, S, Zaniboni, A, Pella, N, Belvedere, O, Beretta, G D, Grossi, F, Frontini, L, Puglisi, F, Labianca, R, Sobrero, A
Publicado em 2004

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

por Scartozzi, M, Bearzi, I, Mandolesi, A, Giampieri, R, Faloppi, L, Galizia, E, Loupakis, F, Zaniboni, A, Zorzi, F, Biscotti, T, Labianca, R, Falcone, A, Cascinu, S
Publicado em 2011

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR...

por Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A
Publicado em 2008

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Ne...

por Brandes, Alba A., Tosoni, A., Franceschi, E., Blatt, V., Santoro, A., Faedi, M., Amistà, P., Gardiman, M., Labianca, R., Bianchini, C., Ermani, M., Reni, M.
Publicado em 2009

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

por Sobrero, A, Grothey, A, Iveson, T, Labianca, R, Yoshino, T, Taieb, J, Maughan, T, Buyse, M, André, T, Meyerhardt, J, Shields, A F, Souglakos, I, Douillard, J -Y, Cervantes, A
Publicado no Ann Oncol (2018)

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.

por Aschele, C., Guglielmi, A., Frassineti, G. L., Milandri, C., Amadori, D., Labianca, R., Vinci, M., Tixi, L., Caroti, C., Ciferri, E., Verdi, E., Rosso, R., Sobrero, A.
Publicado em 1998

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

por Cascinu, S, Silva, R R, Barni, S, Labianca, R, Frontini, L, Piazza, E, Pancera, G, Giordani, P, Giuliodori, L, Pessi, M A, Fusco, V, Luporini, G, Cellerino, R, Catalano, G
Publicado em 1999

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastr...

por Cascinu, S, Scartozzi, M, Labianca, R, Catalano, V, Silva, R R, Barni, S, Zaniboni, A, D'Angelo, A, Salvagni, S, Martignoni, G, Beretta, G D, Graziano, F, Berardi, R, Franciosi, V
Publicado em 2004

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen

por Cascinu, S, Baldelli, A M, Catalano, V, Giordani, P, Beretta, G D, Silva, R R, Gasparini, G, Mari, D, Maisano, R, Salvagni, S, Barni, S, Labianca, R, Frontini, L, Curti, C, Catalano, G
Publicado em 2002

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer

por Sobrero, A, Guglielmi, A, Cirillo, M, Recaldin, E, Frassineti, G L, Aschele, C, Ravaioli, A, Testore, P, Caroti, C, Gallo, L, Pessi, M A, Cortesi, E, Turci, D, Grossi, F, Labianca, R
Publicado em 2001

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

por Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicado no Ann Oncol (2017)

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial tr...

por Boni, C, Tiseo, M, Boni, L, Baldini, E, Recchia, F, Barone, C, Grossi, F, Germano, D, Matano, E, Marini, G, Labianca, R, Di Costanzo, F, Bagnulo, A, Pennucci, C, Caroti, C, Mencoboni, M, Zanelli, F, Prochilo, T, Cafferata, M A, Ardizzoni, A
Publicado em 2012

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

por Grothey, A., Sobrero, A.F., Shields, A.F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., Meyerhardt, J.A., Vernerey, D., Yamanaka, T., Boukovinas, I., Meyers, J.P., Renfro, L.A., Niedzwiecki, D., Watanabe, T., Torri, V., Saunders, M., Sargent, D.J., Andre, T., Iveson, T.
Publicado no N Engl J Med (2018)

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population(†)

por Renfro, L. A., Grothey, A., Kerr, D., Haller, D. G., André, T., Van Cutsem, E., Saltz, L., Labianca, R., Loprinzi, C. L., Alberts, S. R., Schmoll, H., Twelves, C., Yothers, G., Sargent, D. J., Sargent, D.J., Green, E., Grothey, A., Alberts, S.R., Shi, Q., Renfro, L.A., Yothers, G., O'Connell, M.J., Wolmark, N., de Gramont, A., Gray, R., Kerr, D., Haller, D.G., Guthrie, K., Buyse, M., Labianca, R., Seitz, J.F., O'Callaghan, C.J., Francini, G., Catalano, P.J., Blanke, C.D., Andre, T., Goldberg, R.M., Benson, A., Twelves, C., Sirzen, F., Cisar, L., Van Cutsem, E., Saltz, L.
Publicado no Ann Oncol (2015)